dual aurora-2/aurora-1 kinase inhibitors (AstraZeneca)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug Namedual aurora-2/aurora-1 kinase inhibitors (AstraZeneca)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Aurora-B inhibitorsSerine/threonine-protein kinase Aurora-A inhibitors
TargetsSerine/threonine-protein kinase Aurora-ASerine/threonine-protein kinase Aurora-B
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A